Decipher Labs

Who are the top shareholders of the Decipher Labs?

The top shareholders of Decipher Labs include Ajjarapu Janakiram with 16.43% and Seshu Srinivas Akula with 3.8%. Individual investors collectively own 80.75% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Decipher Labs include Ajjarapu Janakiram, who holds the largest stake at 16.43%. The highest public shareholder is Seshu Srinivas Akula, with a holding of 3.8%. Additionally, individual investors collectively own a significant portion of the company, accounting for 80.75% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Has Decipher Labs declared dividend?

No Dividend History Available

Who are the peers of the Decipher Labs?

Decipher Labs' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma and Cipla show excellent management and growth, Decipher Labs has below-average growth and capital structure, with a 1-year return of -37.22%.

Peers: The peers of Decipher Labs are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Span Divergent, Unjha Formul., Checkpoint Trend, Vivanza Biosci., and Cian Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Decipher Labs and Unjha Formul. Below Average management risk is noted for Checkpoint Trend, Vivanza Biosci., and Cian Healthcare. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Divi's Lab., Torrent Pharma, Decipher Labs, Unjha Formul., Checkpoint Trend, Vivanza Biosci., and Cian Healthcare. Excellent capital structure is present at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Below Average capital structure is noted for Decipher Labs, and Average capital structure is observed at Unjha Formul. Good capital structure is seen at Torrent Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Cian Healthcare has the lowest at -82.59%. Decipher Labs' 1-year return is -37.22%, which is significantly lower than the highest return and higher than the lowest. Additionally, the six-month return is negative for Decipher Labs, Span Divergent, Unjha Formul., and Vivanza Biosci.

Is Decipher Labs overvalued or undervalued?

As of June 2, 2025, Decipher Labs is considered overvalued with a risky valuation grade, reflected by a negative PE ratio of -2.22, an EV to EBITDA of -1.20, and a year-to-date stock return of -24.62%, significantly underperforming its peers and the Sensex.

As of 2 June 2025, Decipher Labs has moved from an attractive to a risky valuation grade. The company is currently considered overvalued based on its financial metrics, with a PE ratio of -2.22, an EV to EBITDA of -1.20, and a ROCE of -38.00%. These figures indicate significant financial distress and lack of profitability, which is further underscored by a negative PEG ratio of 0.00.<BR><BR>In comparison to its peers, Decipher Labs stands out negatively; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE ratio of 22.99 and an EV to EBITDA of 15.93. The stark contrast in these ratios highlights Decipher Labs' struggles within the pharmaceuticals and biotechnology sector. Additionally, the company's stock has underperformed significantly against the Sensex, with a year-to-date return of -24.62% compared to the Sensex's 5.66%, reinforcing the notion that Decipher Labs is overvalued at its current price of 11.27.

What is the technical trend for Decipher Labs?

As of June 4, 2025, Decipher Labs is in a bearish trend with moderate strength, driven by bearish daily moving averages and Bollinger Bands, despite some mildly bullish MACD signals.

As of 4 June 2025, the technical trend for Decipher Labs has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages, which are bearish, and the weekly and monthly Bollinger Bands also indicating a bearish trend. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall sentiment is dampened by the bearish moving averages and the Dow Theory, which is mildly bearish on both weekly and monthly scales. The stock's performance has significantly lagged behind the Sensex over various time frames, further supporting the bearish outlook.

Who are in the management team of Decipher Labs?

As of March 2022, the management team of Decipher Labs includes Sushant Mohan Lal (Executive Director), G Venkateswara Rao (Independent Director), and Megha Agarwal (Company Secretary and Compliance Officer).

As of March 2022, the management team of Decipher Labs includes Sushant Mohan Lal, who serves as the Executive Director, G Venkateswara Rao, who is an Independent Director, and Megha Agarwal, who holds the position of Company Secretary and Compliance Officer.

What does Decipher Labs do?

Decipher Labs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 35 Cr and a net loss of 41 Cr for the quarter ending March 2025. The company has a market cap of INR 12 Cr and is based in Hyderabad, India.

Overview:<BR>Decipher Labs Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Decipher Labs Ltd was incorporated as a Private Limited Company in September 1986 and transitioned to a Public Limited Company in June 1992. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 35 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -41 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 12 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.11 <BR>Return on Equity: -22.22% <BR>Price to Book: 0.52<BR><BR>Contact Details:<BR>Address: 4th Flr Plot-94 Sagar Society, Banjara Hills Road No 2 Hyderabad Telangana : 500034 <BR>Email: info@combatdrugs.in <BR>Website: http://www.combatdrugs.in

How big is Decipher Labs?

As of 24th July, Decipher Labs Ltd has a market capitalization of 11.00 Cr and reported net sales of 22.61 Cr with a net loss of 5.08 Cr over the latest four quarters. Shareholder's funds were 21.86 Cr, and total assets were 33.08 Cr as of March 2024.

As of 24th July, Decipher Labs Ltd has a market capitalization of 11.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Decipher Labs reported net sales of 22.61 Cr. However, the company experienced a net loss of 5.08 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, where the shareholder's funds amounted to 21.86 Cr, and total assets were reported at 33.08 Cr.

How has been the historical performance of Decipher Labs?

Decipher Labs has experienced a significant decline in net sales and profitability from March 2022 to March 2025, with net sales dropping from 65.32 Cr to 22.61 Cr and operating profit turning negative, resulting in a loss of 5.08 Cr after tax. Total assets and liabilities also decreased during this period, alongside a negative cash flow from operating activities.

Answer:<BR>The historical performance of Decipher Labs shows a significant decline in net sales and profitability over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Decipher Labs experienced a decrease in net sales from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. This downward trend is reflected in total operating income, which also fell from 65.32 Cr in March 2022 to 22.61 Cr in March 2025. The company's total expenditure, excluding depreciation, peaked at 59.29 Cr in March 2022 but decreased to 29.84 Cr by March 2025. Operating profit (PBDIT) turned negative, going from a profit of 6.03 Cr in March 2022 to a loss of 7.23 Cr in March 2025. Consequently, profit after tax also declined sharply, from 11.38 Cr in March 2022 to a loss of 5.08 Cr in March 2025. The company's total assets decreased from 41.95 Cr in March 2022 to 23.89 Cr in March 2025, while total liabilities also fell from 41.95 Cr to 23.89 Cr in the same period. Cash flow from operating activities showed a negative trend, with a cash outflow of 9.00 Cr in March 2025, compared to a positive inflow of 8.00 Cr in March 2022. Overall, Decipher Labs has faced significant challenges in maintaining sales and profitability over the years.

When is the next results date for Decipher Labs Ltd?

The next results date for Decipher Labs Ltd is 30 May 2026.

The next results date for Decipher Labs Ltd is scheduled for 30 May 2026.

Are Decipher Labs Ltd latest results good or bad?

Decipher Labs Ltd's latest results are concerning, showing a net loss of ₹0.36 crores in Q4 FY26, a 33.33% increase in losses from the previous quarter, despite a slight revenue increase. The company continues to struggle with profitability and operational efficiency, raising doubts about its long-term viability.

Decipher Labs Ltd's latest results present a mixed picture, leaning more towards negative than positive. In Q4 FY26, the company reported a net loss of ₹0.36 crores, which is a 33.33% increase in losses compared to the previous quarter. While there was a slight improvement in revenue, with net sales rising to ₹3.60 crores (a 12.15% increase QoQ and 2.86% YoY), this growth is considered minimal for a pharmaceutical firm.<BR><BR>The operating margin did show some recovery, reaching 6.11% compared to -13.08% in Q3 FY26, indicating a marginal operational improvement. However, the profit after tax (PAT) margin remains deeply negative at -10.00%, although it improved from -16.82% in the previous quarter.<BR><BR>Overall, the company's financial performance reveals ongoing struggles with profitability and operational efficiency. The persistent net losses, combined with a significant decline in revenue over the past fiscal year, raise concerns about its long-term viability. Additionally, the stock has significantly underperformed compared to the broader market, reflecting investor skepticism about its recovery prospects. Thus, the latest results can be characterized as concerning, with multiple red flags indicating that the company is still facing substantial challenges.

Should I buy, sell or hold Decipher Labs Ltd?

Why is Decipher Labs Ltd falling/rising?

As of 02-Jun, Decipher Labs Ltd's stock price is at 7.50, down 0.66%, with significant declines in performance, including a year-to-date drop of 28.23%. The company has reported negative results for seven consecutive quarters, indicating financial distress and waning investor interest.

As of 02-Jun, Decipher Labs Ltd's stock price is currently at 7.50, reflecting a decrease of 0.05, or 0.66%. The stock has shown a significant decline in its performance over various time frames, with a year-to-date drop of 28.23% and a one-year decline of 34.21%. This underperformance is starkly contrasted with the benchmark Sensex, which has only fallen by 12.40% over the same period.<BR><BR>The company's financial health is concerning, as it has reported negative results for the last seven consecutive quarters, with net sales and profit after tax both declining by 26.77% in the latest six months. Additionally, the company has a weak long-term fundamental strength, evidenced by a staggering -208.36% compound annual growth rate (CAGR) in operating profits over the last five years. The negative EBITDA of Rs. -3.4 crore further indicates financial distress.<BR><BR>Investor participation has also decreased, with a delivery volume drop of 26.68% against the five-day average, suggesting waning interest among investors. Although the stock is trading above its shorter-term moving averages, it remains below its longer-term averages, indicating a lack of sustained upward momentum.<BR><BR>Overall, the combination of poor financial performance, declining investor interest, and consistent underperformance against benchmarks contributes to the falling stock price of Decipher Labs Ltd.

Which are the latest news on Decipher Labs?